TLR9

維基百科,自由的百科全書
Toll-like receptor 9
標識
代號 TLR9; CD289
擴展標識 遺傳學605474 鼠基因1932389 同源基因68126 ChEMBL: 5804 GeneCards: TLR9 Gene
直系同源體
物種 人類 小鼠
Entrez 54106 81897
Ensembl ENSG00000239732 ENSMUSG00000045322
UniProt Q9NR96 Q9EQU3
mRNA序列 NM_017442 NM_031178
蛋白序列 NP_059138 NP_112455
基因位置 Chr 3:
52.22 – 52.23 Mb
Chr 9:
106.22 – 106.23 Mb
PubMed查詢 [1] [2]

Toll樣受體9(英語:Toll-like receptor 9)是由人類基因 TLR9 編碼的蛋白質[1],也被稱為CD289分化簇289,cluster of differentiation 289),是Toll樣受體(TLR)家族的成員。

功能[編輯]

TLR家族的受體在病原識別與先天免疫的激活中起著基礎作用。TLRs are named for the high degree of conservation in structure and function seen between mammalian TLRs and the Drosophila transmembrane protein Toll. TLRs是呈現在細胞表面和胞內間室的跨膜蛋白,用以識別病原體呈現的病原相關分子模式(Pathogen-associated molecular patterns,PAMPs),然後啟動製造先天獲得性免疫所需的細胞因子的信號。 The various TLRs exhibit different patterns of expression. 這一基因通常表達於富含免疫細胞的組織,比如淋巴結骨髓等。研究指出,在小鼠和人中的TLR9受體可響應細菌DNA中的未甲基化的CpG寡脫氧核苷酸序列來激活先天免疫應答[2]

TLR9可以識別DNA分子中的未甲基化CpG序列CpG位點在脊椎動物非常稀少(~1%),但在細菌或病毒基因組中很豐富。TLR9在免疫系統的多種細胞中有表達,如B淋巴細胞單核細胞自然殺傷細胞(NK)漿細胞樣樹突狀細胞。TLR9表達於細胞內,是核內體的組分之一,其功能為當細菌或病毒感染時結合其DNA上的富CpG基序來改變免疫系統的狀態。TLR9的信號會導致細胞啟動炎症反應,並分泌相關細胞因子,如I型干擾素IL-12等。

臨床意義[編輯]

There are new immunomodulatory treatments undergoing testing which involve the administration of artificial DNA oligonucleotides containing the CpG motif. CpG DNA has applications in treating allergies such as asthma,[3] immunostimulation against cancer,[4] immunostimulation against pathogens, and as adjuvants in vaccines.[5]

蛋白質相互作用[編輯]

參考文獻[編輯]

  1. ^ Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw. Dec 2000, 11 (3): 362–71. PMID 11022119. 
  2. ^ Entrez Gene: TLR9 toll-like receptor 9. 
  3. ^ Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc. July 2007, 4 (3): 283–8. PMC 2647631可免費查閱. PMID 17607014. doi:10.1513/pats.200701-019AW. 
  4. ^ Thompson JA, Kuzel T, Bukowski R, Masciari F, Schmalbach T. Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). July 2004, 22 (14S) [2016-01-14]. (原始內容存檔於2012-03-08). 
  5. ^ Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 2006, 25 (3-4): 135–54. PMID 16818369. doi:10.1080/08830180600743057. 
  6. ^ Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. May 2004, 5 (5): 495–502. PMID 15107846. doi:10.1038/ni1066. 

延伸閱讀[編輯]

外部連結[編輯]



TLR9引用了美國國家醫學圖書館提供的資料,這些資料屬於公共領域